The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of learning program on treatment recommendations by molecular tumor boards and an artificial intelligence-based annotation system: A prospective study.
 
Kuniko Sunami
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Lilly; Novartis; Riken Genesis; Sysmex
Research Funding - Sysmex
 
Yoichi Naito
Consulting or Advisory Role - AstraZeneca; Bayer; Chugai Pharma; Daiichi Sankyo; Lilly; Pfizer; Taiho Pharmaceutical; Takeda
Speakers' Bureau - AstraZeneca Canada; Bayer Yakuhin; Chugai Pharma; Fujifilm; Gardant Pharmaceuticals; Lilly; Mundipharma; Novartis; Ono Yakuhin; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie; AstraZeneca Japan; Boehringer Ingelheim; Daiichi Sankyo; Eisai; Lilly; Pfizer; Taiho Pharmaceutical
 
Toraji Amano
No Relationships to Disclose
 
Daisuke Ennishi
Honoraria - Chugai Pharma; Eisai; Kirin Pharmaceuticals
Research Funding - Chugai Pharma; Nippon Shinyaku
 
Mitsuho Imai
No Relationships to Disclose
 
Hidenori Kage
Research Funding - Konica Minolta (Inst)
 
Masashi Kanai
Stock and Other Ownership Interests - Therabiopharma Inc.
Speakers' Bureau - Chugai Pharma
Research Funding - MolecularHealth
 
Hirotsugu Kenmotsu
Honoraria - AstraZeneca; Bayer Yakuhin; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi-Sankyo; Kyowa Hakko Kirin; Lilly; Merck; MSD K.K; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Loxo (Inst); Novartis (Inst)
 
Keigo Komine
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo; Kyowa Kirin International; Merck Serono; Taiho Pharmaceutical; Takeda
 
Takafumi Koyama
No Relationships to Disclose
 
Takahiro Maeda
Honoraria - Astellas Amgen BioPharama; Daiichi Sankyo; Eisai; Kyowa Kirin; Novartis; Otsuka; Takeda
Consulting or Advisory Role - Otsuka
Research Funding - Kyowa Kirin
 
Sachi Morita
No Relationships to Disclose
 
Yusuke Saigusa
No Relationships to Disclose
 
Daisuke Sakai
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo/UCB Japan
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo; Eisai (Inst); Incyte (Inst); Lilly Japan; Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Ichiro Kinoshita
Honoraria - AstraZeneca/Daiichi Sankyo; Bayer; Chugai Pharma; Ono Pharmaceutical
 
Toshiyuki Kozuki
Honoraria - Abbvie; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Merck; MSD; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dizal Pharma (Inst); Eisai (Inst); Kyowa-Hakko Kirin (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Hiroyuki Sakashita
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Chugai Pharma (I); Daiichi Sankyo; Nippon Kayaku; Novartis (I); Ono Pharmaceutical; Taiho Pharmaceutical
 
Shinji Kohsaka
Research Funding - AstraZeneca; Boehringer Ingelheim; Chordia Therapeutics; Eisai
 
Katsuya Tsuchihara
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Miyarisan pharmaceutical; Novartis; Takeda
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Genomedia (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)